USD 48.42 Billion
Report ID:
SQMIG35G2308 |
Region:
Global |
Published Date: January, 2025
Pages:
189
|Tables:
89
|Figures:
68
Global Immune Checkpoint Inhibitors Market size was valued at USD 48.42 Billion in 2023 and is poised to grow from USD 57.09 Billion in 2024 to USD 213.13 Billion by 2032, growing at a CAGR of 17.9% in the forecast period (2025-2032).
The growing prevalence of cancer such as lung, breast, bladder, and cervical cancer along with melanomas, and Hodgkin lymphoma has led to a wider use of immune checkpoint inhibitor treatment. According to the Canadian Cancer Society, two in five Canadians are estimated to be diagnosed with cancer in their lifetime and one in four is likely to die due to the disease in the country. The incidence of the disease is rising steadily, which is expected to boost demand for effective diagnostic methods, including immune checkpoint inhibitors. Increasing focus on development of novel immune checkpoint inhibitors by numerous research organizations is projected to positively impact the market growth during the forecast period. Despite these barriers, the immune checkpoint inhibitors market shows strong growth potential, particularly in emerging economies.
The checkpoint inhibitor pembrolizumab for the treatment of MSI-H and dMMR tumors was the first FDA approval based exclusively on the presence of a genetic feature in a tumor. There is continuing competition in the immune checkpoint inhibitors market that has resulted in the growth of the market. Additionally, rising technological advancements in the treatment of cancer and increasing awareness among the population regarding immune system disease are restraining the growth of the immune checkpoint inhibitors market.
Market snapshot - (2025-2032)
Global Market Size
USD 48.42 Billion
Largest Segment
Hospitals Pharmacies
Fastest Growth
Online Pharmacies
Growth Rate
17.9% CAGR
To get more reports on the above market click here to Buy The Report
The global immune checkpoint inhibitors market is segmented into type, application, distribution channel and region. Based on type, the market is segmented into CTLA-4 inhibitor, PD-1 inhibitor and PD-L1 inhibitor. Based on application, the market is segmented into lung cancer, bladder cancer, melanoma, hodgkin lymphoma, colorectal cancer and others. Based on distribution channel, the market is segmented into hospitals pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
As per global immune checkpoint inhibitors market analysis, the hospitals pharmacies segment dominated the market with the largest revenue share of 57.06% in 2024. Immunotherapy treatments including immune checkpoint inhibitor drugs are more frequently conducted in hospital settings compared to other healthcare environments. This is attributed to the widespread availability of hospitals for primary care in numerous developing economies and a favourable reimbursement structure. Furthermore, increasing collaborations between pharmaceutical companies, academic institutions, and hospitals can facilitate access to clinical trials and early drug adoption. According to a 2023 study, supported by AstraZeneca and the National Institute of Cancer, durvalumab, offers a promising therapeutic option in patients suffering from non-small cell lung cancer. Such partnerships can drive the integration of immune checkpoint inhibitors into hospital pharmacies for cancer care, thereby propelling the segment growth.
As per global immune checkpoint inhibitors market outlook, the online pharmacies segment is projected to witness at the fastest CAGR during the forecast period. Online pharmacies offer a convenient and accessible platform for patients to order and receive immune checkpoint inhibitor-based drugs. The increasing adoption of digital health solutions and telemedicine has facilitated the growth of online pharmacies. Patients receive prescriptions digitally and choose online platforms for the procurement of immune checkpoint inhibitors, aligning with broader trends in virtual healthcare. Growing internet accessibility globally contributes to the expansion of online pharmacies. Patients can easily access information about immune checkpoint inhibitors, compare products, and make informed decisions from the comfort of their homes.
The lung cancer segment dominated the market with the largest revenue share of 26.41% in 2023. Rising prevalence and mortality due to lung cancer is a key factor contributing to the segment growth. In addition, companies operating in the market are continuously involved in the development and launch of novel immune checkpoint inhibitors for treatment of patients with lung cancer. For instance, in January 2023, Merck & Co., Inc. received approval for KEYTRUDA (pembrolizumab) as an alternative treatment option for patients following platinum-based chemotherapy and surgical resection. The drug is indicated for patients with stage IB, II, IIIA non-small cell lung cancer. Thus, prominent applications of immune checkpoint inhibitors in treatment are driving segment growth.
The colorectal cancer segment is expected to register at a significant CAGR during the forecast period. The growing prevalence of CRC is one of the primary factors boosting the demand for therapeutics during the forecast period. According to the statistics published by WHO in July 2023, colorectal cancer (CRC) is the third-most common type across the globe. Approximately 1 in 10 cancer patients have CRC. It is the second-leading cause of cancer-related deaths across the world. Moreover, key players in the market are focusing on R&D activities and receiving U.S. FDA approval for treatment of colorectal cancer.
To get detailed analysis on other segments, Request For Free Sample Report
North America dominated the immune checkpoint inhibitors market for the largest revenue share of 63.81% in 2024, owing to high prevalence of neoplasms in the region. The increasing government funding and support for the expansion of new drug development for cancer treatment. Moreover, boost in research and development for new and novel drugs in the market is also supporting the regional growth. The government's help through funding for new drug development for the treatment of cancer is driving the growth of the immune checkpoint inhibitors market. Moreover, the escalating prevalence of cancer in the region amplifies the demand for these treatments.
The immune checkpoint inhibitors market in Asia Pacific is anticipated to witness a significant CAGR during the forecast period, owing to several factors, such as increasing healthcare reforms. Other factors contributing to market growth are improving healthcare infrastructure, a growing population, and rising number of local companies entering the market. Moreover, Asia Pacific has a large population and a high prevalence of cancer. According to Global Cancer Statistics, the estimated number of new cases of cancer in Asia in 2022 was 10.5 million. In addition, increasing focus on the development and approval of immune checkpoint inhibitors by key operating players in the market is projected to fuel the market during the forecast period.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advancements in Immunotherapy
Increasing Approvals and Indications
High Cost of Treatment
Impact on Patients and Healthcare Systems
Request Free Customization of this report to help us to meet your business objectives.
The global immune checkpoint inhibitors market is characterized by intense competition among a mix of established pharmaceutical giants and emerging biotechnology companies. Key players in the market include Merck & Co., Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer, which dominate due to their extensive product portfolios, robust R&D capabilities, and strong global presence. The competitive landscape of the global immune checkpoint inhibitors market is dynamic and multifaceted, driven by innovation, strategic partnerships, and a relentless pursuit of market leadership.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to SkyQuest analysis, immune checkpoint inhibitors enhance the immune system's ability to identify and attack cancer cells. They have shown significant effectiveness against various cancers, such as melanoma, lung cancer, and renal cell carcinoma. The growing adoption of these therapies is supported by extensive clinical trials, favourable regulatory approvals, and their integration into established treatment protocols, all of which drive global immune checkpoint inhibitors market growth. Moreover, the technological advancement in the screening or broadcast method for cancer and increasing healthcare expenditures in this market. The increase in the adoption of immune checkpoint inhibitor drugs in emerging markets, are factors propelling the growth of the immune checkpoint inhibitors market. Furthermore, severe FDA guidelines for the drug approval of new drugs & adverse effects, challenge the growth of the global immune checkpoint inhibitors industry.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 48.42 Billion |
Market size value in 2032 | USD 213.13 Billion |
Growth Rate | 17.9% |
Base year | 2024 |
Forecast period | (2025-2032) |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Immune Checkpoint Inhibitors Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Immune Checkpoint Inhibitors Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Immune Checkpoint Inhibitors Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Immune Checkpoint Inhibitors Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35G2308
[email protected]
USA +1 351-333-4748